We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 66.26+2.9%4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen8/16/2006 11:34:33 AM
   of 347
GenoMed's Treatment Speeds Up Texas Policeman's Recovery from West Nile Paralysis

David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933

ST. LOUIS—August 16, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced that a Texas policeman with paralysis from the waist down due to West Nile virus has accelerated his recovery since starting GenoMed's treatment last week.

The patient contracted West Nile virus encephalitis a month ago. On Monday of that week he was fine, but by Friday, his legs were so weak that he could only get around by crawling. Although he was hospitalized for the next two weeks, he showed little improvement and had become discouraged.

Last week, on Thursday afternoon, August 10th, the patient and his physician began GenoMed's protocol. Two days later, on Saturday, August 12th, the patient walked with assistance for 100 steps, compared to only 18 steps on Friday, the day before. Yesterday, Tuesday, August 15th, the patient could easily move the toes in his right foot for the first time, as well as begin to move his right foot sideways.

Said GenoMed's CEO and Chief Medical Officer, David Moskowitz MD, FACP, "This patient's accelerated recovery from West Nile virus reinforces the idea that our treatment should be used early in all patients suspected of West Nile virus encephalitis. It is possible that he might not have progressed to paralysis if his physician had started him on our treatment during the very first week of symptoms."

Added Dr. Moskowitz, "Getting the word out about our treatment may literally make the difference between life and death, or in this case a quick recovery versus prolonged paralysis."

About GenoMed

Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 87% treatment success rate (20 of 23 patients). The first 8 patients were published two years ago in a peer-reviewed medical journal, and GenoMed still has the only published treatment for West Nile virus encephalitis in the medical literature. This summer GenoMed extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website,, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext